ARTICLE | Clinical News
Evidation, Lilly and Apple show digital tech could identify, monitor Alzheimer’s
August 8, 2019 6:39 PM UTC
Data from a study by Evidation, Eli Lilly and Apple suggest digital biomarkers collected via mobile devices could be used to identify patients at risk for mild cognitive impairment or Alzheimer’s, better stratify patients for cognition-related trials and monitor patients for treatment benefit in clinical studies.
The study showed that an iPhone, Apple Watch, iPad and Beddit sleep monitoring device in combination with digital apps could differentiate between people with mild cognitive impairment and AD...